GRI Bio, Inc. (GRI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
GRI Bio, Inc. (GRI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On November 4, 2026, at 11:00 a.m. Eastern Time, GRI Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockhol
How this was made
The 30-second read
Why it matters
The amendment increases authorized shares by 546,529, modestly diluting existing equity and may affect share price perception.
Market read
Primary corporate action with modest dilution risk; limited immediate trading impact.
What to watch
The extended evergreen provision to 2036 could enable future equity grants tied to long‑term milestones.
Background
GRI Bio filed an 8‑K reporting amendments to its equity incentive plan and director elections, a routine corporate governance update.
Ticker impact
SEC Form 8‑K discloses amendment to the 2018 Equity Incentive Plan and election of new directors, a primary corporate action for GRI Bio.
likely slight downward pressure as the market prices potential dilution
First‑report filing; no immediate financial impact disclosed, but dilution risk is typical for such plan expansions.
Market effects
Minimal; biotech sector sees routine equity plan updates without broader impact.
U.S. market only, no regional ripple.
Low; limited to GRI Bio shareholders.
Counterpoint
Investors may view the plan expansion as a sign of upcoming hiring or acquisitions, potentially supporting upside.
Key entities
- companyGRI Bio, Inc.
Biotech firm filing the 8‑K.
- personW. Marc Hertz, Ph.D.
Elected director.
- personDavid Szekeres
Elected director.


